Company Description
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer.
Its development pipeline includes VTP-1000, an antigen-specific immune tolerance candidate for celiac diseases; VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.
It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older.
Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus.
The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023.
Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.
| Country | United Kingdom |
| Founded | 2016 |
| IPO Date | Apr 30, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 105 |
| CEO | William Enright |
Contact Details
Address: Zeus Building, Unit 6-10 Didcot, OX11 0DF United Kingdom | |
| Phone | 44 1865 818 808 |
| Website | barinthusbio.com |
Stock Details
| Ticker Symbol | BRNS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001828185 |
| CUSIP Number | 91864C107 |
| ISIN Number | US91864C1071 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| William J. Enright MBA | Chief Executive Officer and Director |
| Elizabeth Eagling-Vose M.B.A. | Head of Clinical Operations |
| Bernie McDonald | Head of IP |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 25, 2025 | ARS | Filing |
| Apr 25, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 25, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 20, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 20, 2025 | 10-K | Annual Report |
| Mar 20, 2025 | 8-K | Current Report |
| Feb 11, 2025 | SCHEDULE 13G/A | Filing |
| Jan 10, 2025 | 8-K | Current Report |
| Nov 25, 2024 | 8-K | Current Report |
| Nov 15, 2024 | 8-K | Current Report |